argenx SE (ARGX)
Pre-market:
| Previous close | 375.08 |
| Open | 380.85 |
| Bid | 374.19 x 100 |
| Ask | 376.71 x 100 |
| Day's range | 372.68 - 380.85 |
| 52-week range | 327.73 - 550.76 |
| Volume | |
| Avg. volume | 289,535 |
| Market cap | 22.287B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.18 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 478.76 |
GlobeNewswireargenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE tri
Insider MonkeyHere’s Why argenx SE (ARGX) Pulled Back 23% in Q4
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]
- GlobeNewswire
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease (SjD)
